- Home
- TONX vs EDIT Comparison
TONX vs EDIT Comparison
Compare TONX & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TONX
- EDIT
- Stock Information
- Founded
- TONX N/A
- EDIT 2013
- Country
- TONX United States
- EDIT United States
- Employees
- TONX N/A
- EDIT N/A
- Industry
- TONX Other Consumer Services
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TONX Consumer Discretionary
- EDIT Health Care
- Exchange
- TONX Nasdaq
- EDIT Nasdaq
- Market Cap
- TONX 248.4M
- EDIT 269.8M
- IPO Year
- TONX N/A
- EDIT 2016
- Fundamental
- Price
- TONX $3.93
- EDIT $3.53
- Analyst Decision
- TONX
- EDIT Buy
- Analyst Count
- TONX 0
- EDIT 11
- Target Price
- TONX N/A
- EDIT $4.56
- AVG Volume (30 Days)
- TONX 874.2K
- EDIT 3.1M
- Earning Date
- TONX 11-14-2025
- EDIT 10-31-2025
- Dividend Yield
- TONX N/A
- EDIT N/A
- EPS Growth
- TONX N/A
- EDIT N/A
- EPS
- TONX N/A
- EDIT N/A
- Revenue
- TONX $4,279,000.00
- EDIT $38,901,000.00
- Revenue This Year
- TONX $526.82
- EDIT N/A
- Revenue Next Year
- TONX $45.45
- EDIT N/A
- P/E Ratio
- TONX N/A
- EDIT N/A
- Revenue Growth
- TONX 4095.10
- EDIT N/A
- 52 Week Low
- TONX $3.46
- EDIT $0.91
- 52 Week High
- TONX $13.90
- EDIT $4.54
- Technical
- Relative Strength Index (RSI)
- TONX N/A
- EDIT 48.75
- Support Level
- TONX N/A
- EDIT $3.48
- Resistance Level
- TONX N/A
- EDIT $3.87
- Average True Range (ATR)
- TONX 0.00
- EDIT 0.37
- MACD
- TONX 0.00
- EDIT -0.07
- Stochastic Oscillator
- TONX 0.00
- EDIT 17.24
About TONX TON Strategy Company Common Stock
TON Strategy Co is a leader in interactive video-based sales applications, transforms how businesses attract and engage customers. The company's Software-as-a-Service platform, based on its proprietary interactive video technology, comprises a suite of easy-to-use, subscription-based sales enablement software products. The segments of the company are MARKET.live and Go Fund Yourself, and it derives maximum revenue from MARKET.live segment.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.